Research Outcomes and Recommendations for the Assessment of Progression in Cancer Clinical Trials

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.23, Iss.5, 2013-09, pp. : 949-950

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials?

By Dancey Janet E.

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1728-1730

Blackwell Publishing

Access to resources Recommend Favorite

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials

By Varkaris Andreas Corn Paul G Gaur Sanchaika Dayyani Farshid Logothetis Christopher J Gallick Gary E

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 12, 2011-12 ,pp. : 1677-1684

Informa Healthcare

Access to resources Recommend Favorite

Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials

By Matulonis Ursula A. Oza Amit M. Ho Tony W. Ledermann Jonathan A.

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1737-1746

Blackwell Publishing

Access to resources Recommend Favorite

CONSORT recommendations for reporting harms in clinical trials

Reactions Weekly, Vol. 1, Iss. 1031, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

CONSORT recommendations for reporting harms in clinical trials

Inpharma, Vol. 1, Iss. 1467, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite